Context: Thyroid nodules are very common, and 7% to 15% of them are diagnosed as thyroid cancer. However, the inherited genetic risk factors for thyroid nodules and their associations with thyroid cancer remain unknown.
T hyroid nodules are a common endocrine problem, and their prevalence in the adult population has been 19% to 68% as evaluated using high-resolution ultrasonography (1) . The prevalence of thyroid nodules especially increases with age, and the process of thyroid nodule development has been explained by an increased exposure to environmental factors or as an aging phenomenon (2, 3) . The clinical importance of thyroid nodules rests with the possibility of thyroid cancer, which accounts for 7% to 15% of thyroid nodules (1) . Similar to thyroid cancer, old age, female sex, obesity, smoking, iodine deficiency, and radiation exposure are known risk factors for the development of thyroid nodules (4) (5) (6) . Heritability also contributes to their genesis (7) . Several data have suggested that a family history of thyroid nodules is associated with an increased risk of thyroid cancer (8, 9) . Thus, the genetic risks of thyroid cancer and thyroid nodules could be closely related, and the identification of the shared susceptible genetic loci might be useful for establishing a management strategy for thyroid nodules, especially for patients with a positive family history.
The heritability of thyroid cancer has been assumed to be~50%, which is the highest among all the types of cancers (10) . In recent genome-wide association studies (GWASs) of thyroid cancer, several susceptibility loci, such as FOXE1, MBIP/NKX2-1, DIRC3, and NRG1, have been reported to be associated with differentiated thyroid cancer (DTC) (11) (12) (13) (14) . Regarding thyroid nodules, two studies of single nucleotide polymorphism (SNP) analysis have reported an association between benign thyroid nodules and a SNP on MBIP/NKX2-1, which is a known DTC susceptibility locus (15, 16) . These data suggest a common genetic etiology between benign thyroid nodules and DTC; however, no comprehensive genetic analysis, such as a GWAS for thyroid nodules, has been performed to date.
We recently reported 15 signals associated with DTC from a two-stage GWAS that included 1085 patients with DTC and 8884 controls (17) . Among the controls, we could identify the presence of thyroid nodules in 2561 subjects using serial ultrasound examinations with a 2-year interval. Therefore, we conducted a GWAS to identify the susceptibility loci for thyroid nodules and compare them with those for thyroid cancer in a Korean population.
Methods

Study population
Discovery series and thyroid ultrasonography
A discovery genome-wide association scan was conducted in the Ansung cohort, a community-based cohort living in rural Korea. The Ansung cohort is one of the two community-based cohorts of the Korean Association Resource (KARE) project, and detailed information regarding the KARE project has been previously reported (18) . Of 5018 cohort participants, 3161 individuals were evaluated using thyroid ultrasonography from 2011 to 2012. Subsequent thyroid ultrasonography was performed in 2561 of the 3161 participants from 2013 to 2014. Of the 2561 subjects who underwent two consecutive ultrasound scans, 952 had solid nodules and 824 showed normal thyroid glands that persisted on repeated ultrasound images (Fig. 1) . The remaining 785 individuals had pure cystic nodules, nodules that had disappeared, newly appearing nodules, ultrasound evidence of thyroidectomy, or history of thyroid cancer. The disappeared or newly developed nodules were not true solid nodules but were presumed to be part of focal or diffuse thyroiditis. Also, individuals with pure cystic nodules were not included. The characteristics of the participants are described in Supplemental Table 1 . Figure 1 . Subjects from the discovery stage GWAS and the replication studies for thyroid nodules. QC, quality control. 
First replication series and ultrasonography
For the replication study, we used 496 cases with benign solid nodules without features of diffuse or focal thyroiditis and 600 controls showing normal thyroid glands by ultrasonography and normal thyroid function in a thyroid hormone study. All cases and controls were selected from the participants of the Cancer Screening Program at the National Cancer Center, Republic of Korea. None of the subjects with nodules had had a previous diagnosis of thyroid cancer. The characteristics of the subjects are shown in Supplemental Table 1 .
Second replication
For the second replication study, we requested data from the Gene-Environmental Interaction and Phenotype (GENIE) cohort, a subcohort of the Health and Prevention Enhancement, a retrospective, population-based cohort study conducted at the Seoul National University Hospital Gangnam Center in Korea. Detailed information about the GENIE cohort has been previously reported (19) (20) (21) . Among 6579 subjects whose data were analyzed in genome-wide SNP arrays, 5737 had reports of thyroid ultrasound scans in the electronic health record. The thyroid ultrasound results showed that 1485 had solid thyroid nodules and 2500 had normal thyroid glands. The remaining 1752 subjects had pure cysts, nodules with ultrasound features highly suspicious for malignancy, diffuse or focal thyroiditis, an operated thyroid gland, or a history of thyroid cancer. The characteristics of the cases and controls included in the second replication study are shown in Supplemental Table 1 .
Genotyping, imputation, and expression quantitative trait loci analysis
Discovery GWAS and imputation
Genotyping for KARE projects has been described previously (18) . In brief, peripheral blood samples were obtained from the participants, and genomic DNA was extracted from the lymphocytes. Genotyping for the discovery series was performed using the Affymetrix Genome-Wide Human SNP array 5.0 (Affymetrix Inc., Santa Clara, CA). For quality control, individuals with low call rates (,96%), high heterozygosity (.30%), or sex inconsistencies were removed, and subjects with genetic relatedness were excluded using the kinship identical-by-descent coefficient (Z0 .0.8). In total, 141 cases and 133 controls were excluded by the individual quality control procedures. SNPs with a minor allele frequency of ,1%, SNPs with a missing genotype rate of $5%, and SNPs whose genotype frequencies departed from the Hardy-Weinberg equilibrium at P , 1 3 10 26 were excluded. Imputation was performed using the IMPUTE2 software (available at: http:// mathgen.stats.ox.ac.uk/impute/impute_v2.html), and the 1000 genome ASN phase I panel (National Center for Biotechnology Information, build 37, hg19) was used as a reference. For imputation quality control, SNPs with a minor allele frequency ,0.01 or SNP missing rate .0.05 were removed, and the remaining imputed SNPs were combined with the original KARE SNPs. Finally, 811 cases and 691 controls were analyzed, for a total of 3,996,558 markers.
Candidate SNP and genotyping of first replication
From the genome-wide association analysis, the best 1000 SNPs (P , 3 3 10 24 ) were screened, and 27 representative SNPs in 26 distinct genomic regions were selected as candidate markers. We also included two SNPs (rs944289 on MBIP/ NKX2-1 and rs11175834 on MSRB3), previously reported as signals for thyroid cancer (17) (Supplemental Table 2 ). For the replication study, genotyping was performed using the Fluidigm SNP Type Assay platform (Fluidigm Corporation, South San Francisco, CA) for candidate SNPs. All SNPs were successfully genotyped, with call rates .95% and Hardy-Weinberg equilibrium P . 0.001.
Genotyping of second replication
The subjects of the GENIE cohort were genotyped by DNAIink, Inc., using Affymetrix Axiom™ KORV1.1-96 Genotyping Arrays (Affymetrix Inc.). More information on the genotyping, quality control procedures, and imputation can be found in previous reports (20, 21) . We obtained genotypes for the cases and controls for four SNPs that were selected from the discovery GWAS and first replication study.
Comparison of allele frequencies among DTC, thyroid nodules, and normal thyroids
We compared the allele frequencies for SNPs identified from the GWAS for DTC (17) and the present GWAS for thyroid nodules, across the DTC cases, thyroid nodules, and normal thyroids in a genome-wide scan.
Expression quantitative trait loci analysis
We assessed the effect of the associated genotypes on mRNA expression using the public expression quantitative trait loci (eQTL) database (22) . Imputation of gene expression from the discovery series was performed using the PrediXcan package (available at: https://github.com/hakyimlab/PrediXcan/tree/master/ Software) (23) . The thyroid eQTL database (GTEx V6p; 278 thyroid samples) was used as a reference for imputation.
Statistical analysis
Genome-wide associations were performed using PLINK, version 1.90 beta (available at: https://www.cog-genomics. org/plink2), R statistics, version 3.2.3 (R Foundation, Vienna, Austria), and STATA software, version 13.0 (StataCorp LLC, College Station, TX). The genomic inflation factor (l) for the series of GWAS was calculated to check the presence of population substructures. Quantile-quantile plots using the qqman R package (available at: https://cran.r-project.org/web/ packages/qqman) were used to determine whether population stratification was adequately controlled. Manhattan plots were generated using the Integrative Genomics Viewer (available at: http://software.broadinstitute.org/software/igv). In the series of GWAS, replications, and joint analysis, the associations of each SNP were assessed using a logistic regression model adjusted for age and sex to estimate the per-allele ORs with 95% CIs and P values. We further performed a meta-analysis through the results of regression analysis from each of the three case-control groups using PLINK. A fixed-effects model was used to generate ORs with 95% CIs, and the Cochran Q and Higgins I 2 tests were applied to assess heterogeneity in meta-analysis (24) .
Ethics statement
The Ansung cohort subjects provided written informed consent for the discovery GWAS. The participants of the replication study also provided written informed consent. The institutional review board of the National Cancer Center and the institutional review board of the Seoul National University Hospital approved the present research protocol (approval no. NCC2015-0238 and (approval nos. H-1102-012-349 and H-1108-041-372, respectively).
Results
Discovery GWAS
In the discovery series, the genomic inflation factor (l) was 1.0, indicating that no inflation of P values occurred as a result of population stratification. The quantilequantile plots showed no deviations of the observed distribution from the expected null distribution (Supplemental Fig. 1 ). The genome-wide association result for thyroid nodules was demonstrated by the Manhattan plots (Supplemental Fig. 2 ). In the discovery genomewide scan, the most robust signal (rs9952940) located an intron of EPB41L3 on chromosome 18 [P = 1.83 3 10 27 ; Supplemental Figs. 2 and 3(a)]. The second relevant signal (rs3780873) was observed in an intron of ITGB1 (P = 5.54 3 10 26 ). In total, 29 candidate SNPs in 27 independent loci were selected for the validation study (Supplemental Table 2 ).
Replication studies, joint analysis, and meta-analysis Among the 29 candidate SNPs, one signal, rs9952940 at EPB41L3, which showed the most robust association in the stage 1 genome scan, reached statistical significance in the first replication study (P = 0.045). The OR for rs4745021 at TRPM3 and rs2415317 and rs944289 at MBIP/NKX2-1 in the replication study showed similar trends with the discovery GWAS, with marginal statistical significance (P = 0.065, P = 0.087, and P = 0.095, respectively). We selected these SNPs for the second replication study. In the second replication study, variants at TRPM3 and MBIP/NKX2-1 were significantly associated statistically with thyroid nodule (rs4745021, P = 1.67 3 10
24
; rs2415317, P = 0.043; rs944289, P = 0.028). However, rs9952940 at EPB41L3 was not replicated (P = 0.114). In a joint analysis, rs4745021 at TRPM3 (P = 6.12 3 10
28
) did not reach the genome-wide significance threshold of P , 5 3 10 28 [ Table 1 ; Fig. 2(a) ]. However, the meta-analysis showed statistical significance (OR, 1.28; 95% CI, 1.18 to 1.40; P = 2.11 3 10
, Q = 0.41, I 2 = 0%). Three other SNPs did not reach genome-wide statistical significance (P , 5 3 10
) in the joint analysis (rs2415317, P = 4.62 3 10
25
; rs944289, P = 8.68 3 10
; rs9952940, P = 1.42 3 10 25 ) or meta-analysis (rs2415317, P = 1.09 3 10 25 ; rs944289, P = 1.52 3 10 25 ; rs9952940, P = 5.24 3 10 26 ; Table 1 ). Considering the relatively small sample size, the associations at MBIP/NKX2-1, which showed marginal and nominal statistical significance in the first and second replication, respectively, might be suggestive loci for thyroid nodules.
The minor allele frequency of the four SNPs (rs4745021, rs2415317, rs944289, and rs9952940) were similar to those of the Asian population in the 1000 genome database (Supplemental Table 3 ). The signal on MSRB3, an identified susceptibility locus for DTC from our previous GWAS, was not replicated in the first validation (P = 0.479; Supplemental Table 2 ).
Comparison of allele frequencies among DTC, thyroid nodules, and normal thyroid
We performed an additional analysis comparing the allele frequencies of 15 DTC susceptibility SNPs discovered in our previous study (17) and two candidate SNPs (rs4745021 at TRPM3 and rs2415317 at MBIP/ NKX2-1) for the thyroid nodules from the present study among subjects with DTC, thyroid nodules, or normal thyroid glands (Table 2) . Among them, two thyroid nodule-associated SNPs (rs4745021 at TRPM3 and rs2415317 at MBIP/NKX2-1), two thyroid cancer-associated SNPs (rs11175834 at MSRB3 and rs34081847 at MBIP/NKX2-1), and an SNP associated with both DTC and nodules (rs944289 at MBIP/NKX2-1) showed similar allele frequencies between the DTC and thyroid nodules. These results suggest that these signals might be shared susceptible loci between DTC and thyroid nodules, suggesting their common genetic etiology. Among these, the signals in MBIP/NKX2-1 [ Fig. 3(a-c) ] are considered to be common susceptibility loci for thyroid cancer and thyroid nodules because their associations with DTC risk have been repeatedly validated in GWASs for DTC. Also, the association with the risk of thyroid nodules was replicated in the present three-stage GWAS. A signal in MSRB3 (rs11175834) showed a substantial association with both thyroid cancer and thyroid nodules in the genome-wide scan. However, the SNP failed to show any association in the replication series of the thyroid nodules. The signal in TRPM3 was not a candidate SNP in the previous study of DTC (17) . The other susceptible loci for thyroid cancers (17) such as NRG1 [rs6996585; (Table 2) , suggesting the genetic susceptibilities for thyroid nodules are distinct from those for thyroid cancer.
eQTL analysis
The imputed expression of the discovery series using PrediXcan revealed that the polymorphism rs4745021 has an eQTL for TRPM3 (ENSG00000083067.18) in thyroid tissue [ Fig. 2(b) ; Supplemental Table 4 ]. Expression data for EPB41L3 (ENSG00000082397.11) did not show a substantial difference among the rs9952940 genotypes at EPB41L3 [Supplemental Fig. 3(b) ; Supplemental Table 4 ]. Although EPB41L3 expression was significantly different according to the rs9952940 genotype in colon tissues [Supplemental Fig. 3(c) ]. The expression data for MBIP, NKX2-1, BRMS1L, PTCSC3, RP11-116N8.4, or LINC00609, which are located near MIBP/NKX2-1, by rs2415317 and rs944289 genotypes were not available from GTEx.
Discussion
In the present three-stage GWAS, the signal in TRPM3 showed the most robust association with thyroid nodules, and those in MIBP/NKX2-1 also demonstrated a possible association. A variant at TRPM3 reached the genome-wide significance threshold in the meta-analysis. However, other associations did not show genome-wide statistical significance in the joint analysis or metaanalysis because of the small number of subjects. Our findings have provided evidence that thyroid nodules might arise from genetic predispositions. Candidate SNPs for thyroid nodules showed a similar trend of an association with thyroid cancer. However, the SNPs with the most risk of thyroid cancer, including NRG1 and FOXE1, did not show any association with thyroid nodules, suggesting a genetic susceptibility of thyroid nodules that is distinct from that of thyroid cancer.
In epidemiologic studies, most thyroid diseases, including thyroid cancer, Graves disease, and hypothyroidism, have been reported to have a large degree of genetic heritability. Approximately 50% to 70% of the predisposition to autoimmune thyroid disease was reported to arise from genetic factors (25) , and inherited genetic factors for thyroid cancer The SNP positions are indexed to the National Center for Biotechnology Information (NCBI) build 37.
Abbreviation: Chr, chromosome. development accounted for 53% (10) . GWASs have been widely applied in the field of thyroid diseases for a decade to identify these genetic factors. Despite the accumulated data from these genetic studies of thyroid disease, a GWAS for thyroid nodules has not been conducted to date. We hypothesized that genetic factors could contribute to the development of thyroid nodules, which could share a common genetic predisposition with thyroid cancer. In the present study, we identified TRPM3 as a susceptibility locus and MBIP/NKX2-1 as a suggestive risk locus for thyroid nodules. A variant on TRPM3 (9q21.13) showed the most robust association in the joint analysis. TRPM3 encodes transient receptor potential cation channel subfamily M member 3, a cation-selective channel related to cellular calcium signaling and homeostasis (26) . TRPM3 was also documented as a component of an ionotropic steroid receptor in insulin-producing b cells (27) . The biological function of TRPM3 in the thyroid gland has not been well defined. Recently, TRPM3 was reported to promote the growth of renal cell carcinoma (28) . Thus, TRPM3 expression could also affect tumorigenesis in thyroid cells.
In the present discovery genome-wide scan, rs2415317 and rs944289 signals were detected near MBIP/NKX2-1, which has been reported to be associated with DTC (11, 17, 29) . The association of subsequent replication studies using an independent population showed a similar trend of OR with marginal or nominal statistical significance. Wang et al. (15) have also reported an association between benign thyroid nodules and rs944289 in a Chinese population. Therefore, although the associations in MBIP/NKX2-1 did not reach genome-wide statistical significance, we could not completely exclude the possibility that variants on MBIP/NKX2-1 have associations with thyroid nodules. Thus, it could be suggested that variants on MBIP/NKX2-1 might not be cancer-specific but play various roles in the neoplastic changes of follicular cells. In the present analysis, rs2415317 and rs944289 also showed a similar association with thyroid cancer (Table 2 ). In addition to MBIP/NKX2-1, SNPs on TRPM3, EPB41L3, and MSRB3 demonstrated similar allele frequencies in thyroid nodules and thyroid cancer. Further studies are needed to confirm whether these variants affect both thyroid cancer and thyroid nodule development.
A signal in EPB41L3 showed the most robust association in discovery GWAS and showed statistical significance only in the first replication study. In the joint analysis, the association with EPB41L3 did not reach genome-wide statistical significance. EPB41L3 (18p11.31; erythrocyte membrane protein band 4.1 like 3) encodes protein 4.1B, which is related to actin binding and the structural constituents of the cytoskeleton (30) . Protein 4.1B is expressed in most mammalian tissues and is prominently localized at the plasma membrane in regions of cell-cell contact (31) . Downregulation of protein 4.1B is frequently observed in tumors, and it is considered a potential tumor suppressor (32) . Polymorphisms in EPB41L3 were documented to be associated with kidney function and sleep duration in other GWASs (33, 34) . Although a cis-eQTL of EPB41L3 was not identified, we could not completely exclude the possibility that variants of EPB41L3 could influence the molecular and biological changes in the thyroid gland via trans-eQTL.
In GWASs for thyroid cancer, several susceptibility loci of DTC, including FOXE1 (9q22.33), MBIP/NKX2-1 (14q13.3), DIRC3 (2q35), and NRG1 (8p12) were validated in diverse populations, and other candidate loci (IMMP2L, RARRES1, SNAPC4/CARD9, BAT, and DHX35) were identified and replicated in specific ethnicities (11) (12) (13) (14) 35) . We also reported seven susceptibility loci (VAV3, PCNXL2, INSR, MRSB3, FHIT, SEPT11, and SLC24A6) associated with DTC (17) . A GWAS for goiters was also conducted and revealed that genetic loci near CAPZB, FGF7, and LOC440389 were associated with thyroid volume (36) . Regarding the GWASs for thyroid function, many susceptibility loci for thyrotropin levels (e.g., PDE10A, PDE8B, VEGFA, CAPZB, NRG1, MBIP, SYN2, IGFBP2, NR3C3, FGF7) and free T4 levels (e.g., FOXE1, B4GALT6 LHX3, DIO1, AADAT) have been identified (37) (38) (39) (40) . In these series of GWASs for various thyroid-related traits, the common variants in several genetic loci, including MBIP/NXK2-1, FOXE1, VAV3, INSR, and NRG1, showed associations with multiple thyroid-related phenotypes, suggesting that thyroid disorders could be closely linked with each other via genetic predispositions (Fig. 4) . However, more studies are required to clarify the shared genetic traits of TRPM3 and MBIP/NXK2-1 between thyroid nodules and thyroid cancer.
No susceptible locus other than TRPM3 and MBIP/ NXK2-1 was identified in thyroid nodules in the present GWAS, and the statistical significance of the associations was not as evident in the present study. Moreover, no association with previously known susceptible loci for thyroid cancer such as NRG1 or FOXE1 was observed (Fig. 4) . These data suggest that the heritability of thyroid nodules might not be as strong and that their genetic susceptibility is distinct from that of thyroid cancer.
Clinically, it is important to properly diagnose a malignancy among the presence of thyroid nodules. The probability of malignancy varies according to the ultrasound characteristics (41) . Thus, fine needle aspiration cytology should be used for the diagnosis according to the recommendations (1, 42, 43) . However, it is still inconclusive whether thyroid nodules should be monitored to prevent missing an occurrence of thyroid cancer among nodules with benign cytologic results. If patients with benign thyroid nodules share a common genetic etiology with patients with thyroid cancer, thyroid nodules should be followed up closely. In a long-term follow-up study of thyroid nodules, the risk of thyroid cancer development from cytologically benign thyroid nodules was reported to be extremely low (44) and was considered to be similar to that of the general population (45) . Thus, repeated evaluations to detect thyroid cancer is not recommended for those with benign thyroid nodules (46) . Consistent with the clinical observations, the genetic traits of thyroid nodules found in the present study seemed to differ from those of thyroid cancer. However, variants on MBIP/NKX2-1 or a few other SNPs are possibly associated with both thyroid nodules and thyroid cancer. Further study is therefore needed to identify the common genetic factors of thyroid cancer and nodules, which could elucidate the association between thyroid cancer and nodules from a genetic perspective.
Although, to the best of our knowledge, the present study is the first GWAS for thyroid nodules, our study had limitations. First, the number of subjects was small, and a detailed pathologic examination of the thyroid nodules was not indicated. Thyroid nodules are not a single disease entity. Most benign thyroid nodules are pathologically diagnosed as hyperplastic nodules and follicular adenomas. Genetic predispositions between hyperplastic nodules and follicular adenomas could be different. Genetic factors could not be detected in the present GWAS, possibly because hyperplastic nodules and follicular adenomas might not share common genetic factors. However, it is not clinically feasible to distinguish thyroid pathology from features of ultrasonography or the cytologic results of fine needle aspiration. In addition, the possibility of thyroid cancer being present among thyroid nodules could not be totally excluded in these cases. Another limitation was that stratification analysis for age and sex could not be performed owing to the limitation of the number of subjects.
In conclusion, to the best of our knowledge, we conducted the first GWAS for thyroid nodules and identified signals in TRPM3 as susceptibility locus and MBIP/NXK2-1 as possible risk locus associated with thyroid nodules. The genetic susceptibility for thyroid nodules was distinct from that for thyroid cancer, although these risk loci, especially on MBIP/NKX2-1, seemed to be shared between them.
